High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status.

MLA

Cortellini, Alessio, et al. “High Familial Burden of Cancer Correlates with Improved Outcome from Immunotherapy in Patients with NSCLC Independent of Somatic DNA Damage Response Gene Status.” Journal of Hematology & Oncology, vol. 15, no. 1, Jan. 2022, p. 9. EBSCOhost, https://doi.org/10.1186/s13045-022-01226-2.

APA

Cortellini, A., Giusti, R., Filetti, M., Citarella, F., Adamo, V., Santini, D., Buti, S., Nigro, O., Cantini, L., Di Maio, M., Aerts, J. G. J. V., Bria, E., Bertolini, F., Ferrara, M. G., Ghidini, M., Grossi, F., Guida, A., Berardi, R., Morabito, A., … Pinato, D. J. (2022). High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status. Journal of Hematology & Oncology, 15(1), 9. https://doi.org/10.1186/s13045-022-01226-2

Chicago

Cortellini, Alessio, Raffaele Giusti, Marco Filetti, Fabrizio Citarella, Vincenzo Adamo, Daniele Santini, Sebastiano Buti, et al. 2022. “High Familial Burden of Cancer Correlates with Improved Outcome from Immunotherapy in Patients with NSCLC Independent of Somatic DNA Damage Response Gene Status.” Journal of Hematology & Oncology 15 (1): 9. doi:10.1186/s13045-022-01226-2.